BR112014025037A2 - anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente - Google Patents
anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagenteInfo
- Publication number
- BR112014025037A2 BR112014025037A2 BR112014025037-5A BR112014025037A BR112014025037A2 BR 112014025037 A2 BR112014025037 A2 BR 112014025037A2 BR 112014025037 A BR112014025037 A BR 112014025037A BR 112014025037 A2 BR112014025037 A2 BR 112014025037A2
- Authority
- BR
- Brazil
- Prior art keywords
- fgfr2 antibody
- fgfr2
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122016008098A BR122016008098A2 (pt) | 2012-04-09 | 2013-04-09 | anticorpo ou fragmento funcional do mesmo, e, composição farmacêutica |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012088299 | 2012-04-09 | ||
JP2012-088299 | 2012-04-09 | ||
PCT/JP2013/061340 WO2013154206A1 (ja) | 2012-04-09 | 2013-04-09 | 抗fgfr2抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014025037A2 true BR112014025037A2 (pt) | 2018-07-31 |
Family
ID=49327760
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016008098A BR122016008098A2 (pt) | 2012-04-09 | 2013-04-09 | anticorpo ou fragmento funcional do mesmo, e, composição farmacêutica |
BR112014025037-5A BR112014025037A2 (pt) | 2012-04-09 | 2013-04-09 | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016008098A BR122016008098A2 (pt) | 2012-04-09 | 2013-04-09 | anticorpo ou fragmento funcional do mesmo, e, composição farmacêutica |
Country Status (20)
Country | Link |
---|---|
US (2) | US9714298B2 (pt) |
EP (1) | EP2837685B1 (pt) |
JP (1) | JP6188681B2 (pt) |
KR (1) | KR102115143B1 (pt) |
CN (1) | CN104334724B (pt) |
AU (1) | AU2013247645B2 (pt) |
BR (2) | BR122016008098A2 (pt) |
CA (1) | CA2870126C (pt) |
CO (1) | CO7111294A2 (pt) |
ES (1) | ES2831309T3 (pt) |
HK (1) | HK1205180A1 (pt) |
IL (1) | IL235004A0 (pt) |
MX (2) | MX360851B (pt) |
NZ (1) | NZ631445A (pt) |
PH (1) | PH12014502269A1 (pt) |
RU (1) | RU2014145001A (pt) |
SG (2) | SG10201608382QA (pt) |
TW (1) | TWI669313B (pt) |
WO (1) | WO2013154206A1 (pt) |
ZA (1) | ZA201407316B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ715201A (en) | 2013-08-01 | 2021-12-24 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
JP6509735B2 (ja) * | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗fgfr2抗体と他剤の組合せ |
IL251834B2 (en) * | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
WO2016163433A1 (ja) * | 2015-04-08 | 2016-10-13 | 第一三共株式会社 | 抗fgfr2抗体と他剤を含む組成物 |
US10881734B2 (en) * | 2015-04-20 | 2021-01-05 | Daiichi Sankyo Company, Limited | Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof |
FI3354729T3 (fi) | 2015-09-24 | 2024-04-23 | Daiichi Sankyo Co Ltd | Anti-garp-vasta-aine |
BR112018010410A8 (pt) * | 2015-11-23 | 2019-02-26 | Five Prime Therapeutics Inc | método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1 |
CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
BR112019023898A2 (pt) | 2017-05-16 | 2020-06-09 | Five Prime Therapeutics Inc | método para tratamento de câncer gástrico, uso de um anticorpo e composição |
EP3685849A4 (en) * | 2017-09-22 | 2021-12-22 | Asahi Kasei Pharma Corporation | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY |
CN116999573A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体-药物偶联物及其制造方法、药物组合物及其在制备***的药物中的应用 |
KR20210143237A (ko) | 2019-03-25 | 2021-11-26 | 다이이찌 산쿄 가부시키가이샤 | 항체-피롤로벤조디아제핀 유도체 컨쥬게이트 |
US20220177601A1 (en) | 2019-03-25 | 2022-06-09 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate |
CA3139180A1 (en) | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
US20220251518A1 (en) * | 2019-07-08 | 2022-08-11 | Terumo Kabushik Kaisha | Hybridoma, method for making the same, monoclonal antibody, and method for making the same |
KR20230129456A (ko) * | 2020-12-29 | 2023-09-08 | 선전 포워드 파머수티컬즈 코 엘티디 | 항-fgfr2 항체 및 이의 용도 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
WO2012021841A2 (en) | 2010-08-12 | 2012-02-16 | Attogen Inc. | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
US20110059091A1 (en) | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
MX2011000455A (es) * | 2008-11-07 | 2011-02-25 | Galaxy Biotech Llc | Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos. |
ES2932874T3 (es) * | 2009-03-25 | 2023-01-27 | Genentech Inc | Anticuerpos anti-FGFR3 y métodos que utilizan los mismos |
EP2569012A4 (en) * | 2010-05-11 | 2013-10-30 | Aveo Pharmaceuticals Inc | ANTI-FGFR2 ANTIBODY |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
-
2013
- 2013-04-09 US US14/391,435 patent/US9714298B2/en active Active
- 2013-04-09 SG SG10201608382QA patent/SG10201608382QA/en unknown
- 2013-04-09 WO PCT/JP2013/061340 patent/WO2013154206A1/ja active Application Filing
- 2013-04-09 ES ES13776053T patent/ES2831309T3/es active Active
- 2013-04-09 CN CN201380030170.8A patent/CN104334724B/zh active Active
- 2013-04-09 RU RU2014145001A patent/RU2014145001A/ru not_active Application Discontinuation
- 2013-04-09 EP EP13776053.4A patent/EP2837685B1/en active Active
- 2013-04-09 SG SG11201406422TA patent/SG11201406422TA/en unknown
- 2013-04-09 BR BR122016008098A patent/BR122016008098A2/pt not_active Application Discontinuation
- 2013-04-09 AU AU2013247645A patent/AU2013247645B2/en not_active Ceased
- 2013-04-09 JP JP2014510224A patent/JP6188681B2/ja active Active
- 2013-04-09 MX MX2014012230A patent/MX360851B/es active IP Right Grant
- 2013-04-09 BR BR112014025037-5A patent/BR112014025037A2/pt not_active Application Discontinuation
- 2013-04-09 TW TW102112440A patent/TWI669313B/zh active
- 2013-04-09 KR KR1020147028003A patent/KR102115143B1/ko active IP Right Grant
- 2013-04-09 NZ NZ631445A patent/NZ631445A/en not_active IP Right Cessation
- 2013-04-09 CA CA2870126A patent/CA2870126C/en active Active
-
2014
- 2014-10-06 IL IL235004A patent/IL235004A0/en unknown
- 2014-10-08 PH PH12014502269A patent/PH12014502269A1/en unknown
- 2014-10-08 ZA ZA2014/07316A patent/ZA201407316B/en unknown
- 2014-10-09 MX MX2018014178A patent/MX2018014178A/es unknown
- 2014-10-23 CO CO14234940A patent/CO7111294A2/es unknown
-
2015
- 2015-06-08 HK HK15105448.0A patent/HK1205180A1/xx unknown
- 2015-07-06 US US14/791,698 patent/US9481733B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2934584T3 (da) | Anti-gdf15-antistoffer | |
DK2850101T3 (da) | Anti-FcRn-antistoffer | |
CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
DK2858671T3 (da) | Antistofformulering | |
DK2859055T3 (da) | Polymercoatings | |
DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
DK2825087T3 (da) | Otoscanner | |
DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
DK3117837T3 (da) | Antistofformuleringer | |
DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
DE112012006109A5 (de) | Okklusionsschienenanordnung | |
DK2854722T3 (da) | Stomipose | |
BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
CR20140127A (es) | Anticuerpo anti-abtcr | |
DK2825157T3 (da) | Aminosyrelipider | |
DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
DK3431504T3 (da) | Antiphospholipase d4-antistof | |
DK2831122T3 (da) | Anthocyanidin-kompleks | |
DK3521315T3 (da) | Anti-transglutaminase-2-antistoffer | |
DE112012006214T8 (de) | Wulstringwickler | |
DK2935330T3 (da) | Anti-notch3-antistoffer | |
DE112012005566T8 (de) | Seltenerdnanoverbundmagnet | |
FI20126082A (fi) | Kaasunvaihtoventtiilijärjestely | |
DK2885638T3 (da) | Molekylenet | |
DK2858657T3 (da) | Feijoafrugtekstrakt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |